Bristol-Myers Squibb expands collaboration with Five Prime Therapeutics in a

The biopharmaceutical company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.36 by $0.17. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the company’s stock.

Himax Technologies, Inc. (HIMX) of the Technology sector is up 4.11% trading at a volume of 454523 shares.

Under the terms of the agreement, Five Prime will receive an upfront payment of $350M, up to $1.05B in development and regulatory milestones for CSF1R oncology indications (including combinations with Opdivo and any other agent), up to $340M in development and regulatory milestones for CSF1R non-oncology indications and double-digit royalties on commercial sales (higher if Five Prime elects to co-promote in the U.S.). Finally, Jefferies Group boosted their price objective on Bristol-Myers Squibb to $60.00 and gave the stock a “hold” rating in a research report on Thursday, September 10th. (NASDAQ:FPRX). The brokerage firm has issued a Buy rating on the shares. Lewis “Rusty” Williams, founder, president and CEO of Five Prime, told BioWorld Today at the time that although he’d considered partnering FPA008 with other pharma companies, he and his team know BMS well “and have a very high regard for them in this field, and for the attributes of nivolumab”. The shares have underperformed the S&P 500 by 4.38% during the past week but Bristol-Myers Squibb Company (NYSE:BMY) has outperformed the index in 4 weeks by 0.98%. Himax Technologies, Inc. (HIMX) is trading at $7.340, with a weekly performance of – 8.080% and gross margin of 24.70%. The total value of the transaction was worth $58,415. Shareholders of record on Friday, October 2nd will be given a dividend of $0.37 per share. This represented a surprise factor of 51.43% as the actual was $0.18 away from the Zacks consensus immediately prior to the release.

According to the latest short-interest data for the two-week period ended September 30, 2015, short interest for the stock of Exelon Corp (EXC) increased from 20497051 shares at the end of the settlement date of September 15, 2015 to 21376573 shares, marking a drop of 879522 shares.

Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, advertising, supply and sale of biopharmaceutical products around the globe. Its products are manufactured by the Company in six foreign nations and in the United States, Puerto Rico. Additionally, it supplies tips regarding the utilization of its products through direct-to-consumer print, radio, tv, and digital advertising and promotion. In addition, the Company holds rights to F001287, which can be a preclinical, little-molecule IDO1 inhibitor.